Samsung Bioepis makes 3rd investment in ADCs
By Son, Hyung-Min | translator Kim, Jung-Ju
24.03.26 12:05:01
가나다라
0
Samsung Bioepis has invested in shares for BrickBio…3rd investment following its previous investments in AimedBio Araris Biotech
Involved in acquiring ADC linker technology…Securing CDMO production capacity while focusing on new drug commercialization
Samsung Group, together with Samsung Bioepis, has made its third investment in companies discovering Antibody-Drug Conjugates (ADCs). Samsung Group plans to actively participate in new drug commercialization through acquiring the original technology as Samsung Biologics expands its CDMO facility for producing ADCs.
Samsung Group announced on the 26th that it has invested in BrickBio, a company focused on developing ADCs, through Life Sciences Fund. Life Sciences Fund is a venture investment fund established jointly with Samsung Bioepis, Samsung C&T Corporation, and Samsung Biologics, collectively pooling KRW 170 billion.
This is Samsung Group’s third investment in companies developing ADCs
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)